CREATE Medicines Achieves Complete B Cell Depletion in Non-Human Primates with In Vivo CAR-T Platform
核心洞察
CREATE Medicines (搜索) demonstrated complete B cell depletion (搜索) in non-human primates using its proprietary in vivo CAR-T (搜索) platform, validating both next-generation T cell receptor (搜索)-specific CAR and conventional 41BBζ CAR designs.
The company's RNA-LNP (搜索) delivery system enables modular CAR deployment and targeted immune cell programming without requiring cell harvesting, manipulation, or conditioning regimens.
CREATE's platform allows for repeatable dosing and integrates CARs into the T cell receptor (搜索) for precise immune cell programming without off-target expression.
CREATE Medicines (搜索) has achieved a significant milestone in in vivo CAR therapy development, demonstrating complete B cell depletion (搜索) in non-human primates using its proprietary platform. The clinical-stage biotechnology company announced these breakthrough results, which validate its differentiated receptor design and targeted RNA-LNP (搜索) platform capabilities.
The company successfully achieved complete B cell depletion (搜索) in non-human primates using both a next-generation T cell receptor (搜索)-specific CAR and a conventional 41BBζ CAR. These results represent what the company describes as "a major leap in the field of in vivo CAR therapies," demonstrating that targeted T cell programming is both achievable and redosable with their platform.
Platform Technology and Advantages
CREATE's in vivo CAR-T (搜索) platform addresses key limitations of traditional ex vivo cell therapies by eliminating the need for cell harvesting, manipulation, or conditioning regimens. The validated RNA-LNP (搜索) delivery system enables modular CAR deployment and targeted immune cell programming directly within the body.
A distinguishing feature of CREATE's approach is its flexible receptor architecture, which enables tailored immune activation, persistence, and control across different indications. The platform's ability to integrate CARs into the T cell receptor (搜索) represents a significant advancement over currently used approaches, allowing for precise immune cell programming without off-target expression.
"The broad potential of our platform across oncology and autoimmune is now validated in both humans and NHPs," said Robert Hofmeister, PhD, Chief Scientific Officer of CREATE Medicines (搜索). "This represents a major leap in the field of in vivo CAR therapies, demonstrating that targeted T cell programming is not only possible, but redosable and clinically de-risked with our platform."
Clinical Development Timeline
CREATE has announced plans for clinical entry in the second half of 2026. The company emphasizes that its platform has achieved proven human validation and is advancing a pipeline of in vivo CAR therapies designed to transform outcomes in both cancer (搜索) and autoimmunity.
CEO and co-founder Daniel Getts highlighted the clinical maturity of the platform, stating that the data "highlight the clinical maturity of our platform and reinforce its ability to safely and repeatedly program immune cells as we advance programs across oncology and autoimmune disease (搜索)."
Multi-Indication Approach
The modularity of CREATE's platform is central to its multi-immune programs, where selective functionality and control are critical for different therapeutic applications. The company's proprietary mRNA-LNP platform is designed to deliver scalable, repeat-dose, off-the-shelf immunotherapies across various indications.
The non-human primate data was presented at the Keystone Symposia: Emerging Cell Therapies conference in Banff, Alberta, under the poster title "In Vivo Generation of CAR-T (搜索) Cells for the Treatment of B Cell Mediated Autoimmunity and Hematological Malignancies (搜索)."